Lung Cancer最新文献

{"title":"Combined intrathecal therapy via Ommaya reservoir and whole-brain radiotherapy improves survival in EGFR-mutant NSCLC patients with leptomeningeal metastases: a real-world cohort study","authors":"Meifang Li ,&nbsp;Haibo Wang ,&nbsp;Wei Zhang ,&nbsp;Dong Lin ,&nbsp;Chongting Gao ,&nbsp;Ying Chen ,&nbsp;Cheng Lin ,&nbsp;Zongyang Yu","doi":"10.1016/j.lungcan.2026.108918","DOIUrl":"10.1016/j.lungcan.2026.108918","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to evaluate the survival benefit of combined intrathecal treatment (IT) via Ommaya reservoir and whole-brain radiotherapy (WBRT) in EGFR-mutant non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM).</div></div><div><h3>Methods</h3><div>We retrospectively analyzed EGFR-mutant NSCLC patients with LM diagnosed between January 2019 and September 2024. Patients were included if they had cytologically or radiologically confirmed LM and prior EGFR-TKI exposure. Clinical data, cerebrospinal fluid (CSF) profiles (cytology, biochemistry, molecular features), and treatment details were collected. Local therapies included WBRT (30–37.5 Gy in 10–15 fractions) and IT pemetrexed via Ommaya reservoir (10–20 mg weekly for 4 weeks, then bi-weekly for 2 months, followed by monthly maintenance). Overall survival (OS) was analyzed using Kaplan-Meier method and Cox regression. A prognostic nomogram was developed and validated.</div></div><div><h3>Results</h3><div>Among 200 included patients, the median OS was 12.3 months (95% CI: 10.8–13.8). Patients receiving local therapy (n = 149) had longer OS than those without (n = 51) (13.1 vs. 8.8 months; HR = 0.78, p = 0.001). The combination of IT and WBRT was associated with the best survival outcome (median OS 18.5 months). In CSF analysis, the initial cytology positivity rate was 74.4% (128/172), and normal lactate dehydrogenase (LDH) and chloride levels were associated with longer OS (p &lt; 0.05). Multivariate analysis identified ECOG score, prior third-generation TKI, third-generation TKI plus anti-angiogenic therapy, and local therapy as independent prognostic factors.</div></div><div><h3>Conclusion</h3><div>The combination of IT via Ommaya reservoir and WBRT may result in better survival in EGFR-mutant NSCLC patients with LM and represents a promising treatment strategy for this patient population.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 108918"},"PeriodicalIF":4.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer","authors":"Jennifer A. Marks ,&nbsp;Kieran Sweeney ,&nbsp;Andrew Elliott ,&nbsp;Brinda Gupta ,&nbsp;Ari VanderWalde ,&nbsp;Sonam Puri ,&nbsp;Misty Dawn Shields ,&nbsp;Jorge J. Nieva ,&nbsp;Heloisa P. Soares ,&nbsp;Patrick C. Ma ,&nbsp;Balazs Halmos ,&nbsp;Stephen V. Liu","doi":"10.1016/j.lungcan.2026.108913","DOIUrl":"10.1016/j.lungcan.2026.108913","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Small cell lung cancer (SCLC) and extrapulmonary neuroendocrine (NE) tumors are aggressive malignancies with limited treatment options. Seizure-related homolog 6 (SEZ6) is a potential therapeutic target, but its expression in these tumors remains poorly understood. Lineage plasticity contributes to resistance in non-small cell lung cancer (NSCLC), where some cases can undergo SCLC-transformation after targeted therapy. We aimed to characterize &lt;em&gt;SEZ6&lt;/em&gt; expression across NE tumors and presumed NSCLC-to-SCLC transformations.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;DNA and RNA sequencing were performed for SCLC, NSCLC, and NE samples. Samples were stratified by SEZ6 RNA expression quartiles and classified into subtypes based on ASCL1, NEUROD1, and POU2F3 expression. Significance was tested using the Mann-Whitney &lt;em&gt;U&lt;/em&gt; test. Real-world overall survival was obtained from insurance claims data, with p-values calculated using the log-rank test. Paired samples for NSCLC-to-SCLC transformation were identified by sequential biopsies classified as NSCLC followed by SCLC.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;RNA sequencing was performed on 1318 SCLC and 2218 NE samples. Median SEZ6&lt;!--&gt; &lt;!--&gt;expression was higher in SCLC (39.7 transcripts per million (TPM)) than in NE tumors (20.8 TPM, p&lt;0.0001) and NSCLC (1.34 TPM, p&lt;0.001). Among NE tumors, median SEZ6 expression was highest in prostate (52.0 TPM, p=0.0016 vs SCLC) and lowest in adrenal gland tumors (1.2 TPM, p&lt;0.0001 vs SCLC). In SCLC,&lt;!--&gt; &lt;!--&gt;SEZ6&lt;!--&gt; &lt;!--&gt;expression was positively correlated with ASCL1&lt;!--&gt; &lt;!--&gt;(p=0.44, p&lt;0.0001) and&lt;!--&gt; &lt;!--&gt;NEUROD1&lt;!--&gt; &lt;!--&gt;(p=0.16, p&lt;0.0001) expression but not&lt;!--&gt; &lt;!--&gt;POU2F3&lt;!--&gt; &lt;!--&gt;(p=-0.04, p=0.1253). Median survival was longest in SEZ6-Q2 for both SCLC and NE (13.0 mos. and 33.7 mos., respectively). NSCLC-to-SCLC transformation samples showed numerically higher SEZ6 expression post-transformation (median: 86.2 vs 2.4 TPM).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;SEZ6&lt;!--&gt; &lt;!--&gt;expression is higher in SCLC than in NE tumors, with notable heterogeneity by subtype, warranting consideration of expanded use of SEZ6-directed therapy.&lt;/div&gt;&lt;div&gt;Translational Relevance Statement:&lt;/div&gt;&lt;div&gt;This study establishes SEZ6 as a promising therapeutic target in small cell lung cancer (SCLC) and transformed non-small cell lung cancer (NSCLC), demonstrating its significantly elevated expression compared to neuroendocrine (NE) tumors and NSCLC. The positive correlation of &lt;em&gt;SEZ6&lt;/em&gt; expression with NE lineage markers, particularly in &lt;em&gt;ASCL1&lt;/em&gt; and &lt;em&gt;NEUROD1&lt;/em&gt; subtypes, highlights its role as a lineage-specific marker, guiding the development of SEZ6-targeted antibody-drug conjugates (ADCs). Additionally, the increased &lt;em&gt;SEZ6&lt;/em&gt; expression following NSCLC-to-SCLC transformation suggests that SEZ6-targeted therapies could address resistance mechanisms in transformed tumors. Importantly, the association be","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 108913"},"PeriodicalIF":4.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations","authors":"Kathleen Zwijsen ,&nbsp;Ellen Heirwegh ,&nbsp;Eline Schillebeeckx ,&nbsp;Elly Marcq ,&nbsp;Adrian Covaci ,&nbsp;Ken Op de Beeck ,&nbsp;Jan P. van Meerbeeck ,&nbsp;Jo Raskin ,&nbsp;Annelies Janssens ,&nbsp;Annemiek Snoeckx ,&nbsp;Kevin Lamote","doi":"10.1016/j.lungcan.2025.108893","DOIUrl":"10.1016/j.lungcan.2025.108893","url":null,"abstract":"<div><h3>Objectives</h3><div>Pleural mesothelioma (PM) is an aggressive thoracic cancer related to historical exposure to asbestos fibres. Symptoms often appear at an advanced stage, leading to delayed diagnosis and dismal prognosis. Early diagnosis is thus crucial in improving patient outcome. Current biomarker research for early detection focuses on different −omics research fields (genomics, proteomics, transcriptomics, metabolomics and volatomics), however with no clinically useful result. Moreover, currently no screening program is advocated for asymptomatic individuals with an established asbestos exposure. The aim of this review is to summarise the advances in different −omics fields and to pinpoint state-of-the art biomarkers with the highest potential to serve as primary targets in clinical trials for early PM detection or screening.</div></div><div><h3>Methods</h3><div>A literature search was performed in the databases MEDLINE and Web Of Science. Research articles published before 1 August 2025 were eligible.</div></div><div><h3>Results</h3><div>In total, 63 articles were included in this review, with specific focus on radiomics, genomics, transcriptomics, epigenomics, proteomics, metabolomics, and volatomics. Several research groups have focused on investigating biomarkers or screening techniques for pleural mesothelioma among individuals with a history of asbestos exposure. Notable approaches include using low-dose Computed Tomography, and determining mesothelin levels and micro-RNAs in blood, and volatile organic compounds in exhaled breath.</div></div><div><h3>Discussion</h3><div>Single biomarkers like miRNAs, mesothelin, and VOCs show promise, but further validation is needed in larger cohorts with correct control groups. A multi-omics approach, which integrates biomarker panels from various −omics areas, has the potential to enhance diagnostic accuracy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108893"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145927314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials","authors":"Deborah Di-Xin Zhou ,&nbsp;Sarah J. Lord ,&nbsp;Frank Po-Yen Lin ,&nbsp;Wendy A. Cooper ,&nbsp;Milita Zaheed ,&nbsp;Robert John Simes ,&nbsp;Thomas John ,&nbsp;Chee Khoon Lee","doi":"10.1016/j.lungcan.2025.108891","DOIUrl":"10.1016/j.lungcan.2025.108891","url":null,"abstract":"<div><h3>Background</h3><div>In NSCLC, <em>TP53</em> mutations are heterogeneous with varied effects on protein synthesis, function and clinical outcomes. We hypothesize that a refined classification of <em>TP53</em> mutations, beyond binary categorization, could improve prognostication. Furthermore, specific mutations could be associated with enhanced benefit from immune checkpoint inhibitors (ICI) versus chemotherapy. To investigate this, we analyzed data from randomized trials (OAK and POPLAR) which compared atezolizumab to chemotherapy in previously treated advanced driver-negative NSCLC.</div></div><div><h3>Methods</h3><div>Participants were classified as <em>TP53</em> mutant or wild-type using baseline plasma, and by coding mutation, and Olivier’s and Poeta’s classification. We performed multivariable Cox regression analyses to evaluate the prognostic significance of <em>TP53</em> mutations, and interaction tests to assess their predictive value.</div></div><div><h3>Results</h3><div>Among 762 participants, 49% harbored a <em>TP53</em> mutation. <em>TP53</em> mutations based on binary categorization were associated with poorer but not statistically significant OS compared to wild-type (adjusted-HR 1.15; 95 %CI 0.96–1.38; <em>P</em> = .12). However, nonsense mutations classified by coding mutations (adjusted-HR 1.71; 95% CI 1.22–2.39;<!--> <em>P</em> = .002), non-missense mutations classified by Olivier’s classification (adjusted-HR 1.33; 95% CI 1.03–1.74; <em>P</em> = .03) and disruptive mutations classified by Poeta’s classification (adjusted-HR 1.33; 95% CI 1.37–1.77; <em>P</em> = .03) were associated with statistically significant poorer OS. <em>TP53</em> status did not predict differential benefit from ICI versus chemotherapy (interaction <em>P</em> = .45).</div></div><div><h3>Conclusion</h3><div>In advanced driver-negative NSCLC following progression on first-line chemotherapy, nonsense, non-missense and disruptive mutations of <em>TP53</em> were strongly associated with inferior OS. These data support utilizing a nuanced classification of <em>TP53</em> mutations as a stratification factor in future trials, and laboratory reporting to aid prognostication.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108891"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"39 Robotic bronchoscopy: diagnostic and marking tool to improve surgical outcomes in management of small peripheral nodules","authors":"Andrea Bille ,&nbsp;Andrea Bille ,&nbsp;Akshay Patel ,&nbsp;Savvas Lampridis ,&nbsp;Tom Routledge ,&nbsp;George Santis","doi":"10.1016/j.lungcan.2026.108988","DOIUrl":"10.1016/j.lungcan.2026.108988","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108988"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"47 Single-centre 10-year experience for Lung neuroendocrine surgery and systemic treatment","authors":"Lauren Armitage ,&nbsp;Mohammed Omar Farooq ,&nbsp;Jason Adhikaree","doi":"10.1016/j.lungcan.2026.108996","DOIUrl":"10.1016/j.lungcan.2026.108996","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108996"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"46 Evaluation of Cardiology Investigations for Oncology Patients on Tyrosine Kinase Inhibitors","authors":"Srishti Agarwal ,&nbsp;Emma Khoury ,&nbsp;Luke Nolan ,&nbsp;Salma Naheed ,&nbsp;Deborah Scott ,&nbsp;Andrew Bates ,&nbsp;Paul Fenton ,&nbsp;Adityanarayan Bhatnagar ,&nbsp;Victoria-Jessica Wood ,&nbsp;Judith Cave","doi":"10.1016/j.lungcan.2026.108995","DOIUrl":"10.1016/j.lungcan.2026.108995","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108995"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"49 MRI head reporting in patients with Lung Cancer August 2024–2025","authors":"Maleeha Mughal ,&nbsp;Emily Hobbs ,&nbsp;WeiTeen Tan ,&nbsp;Emily Scott ,&nbsp;Anna Lerner ,&nbsp;John Conibear ,&nbsp;Pandora Rudd","doi":"10.1016/j.lungcan.2026.108998","DOIUrl":"10.1016/j.lungcan.2026.108998","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108998"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"26 Is Stereotactic ablative radiotherapy (SABR) with curative intent more cost-effective than surgical resection for early-stage non-small lung cancer (NSCLC)? New findings from the SORT study","authors":"Richard Grieve,&nbsp;Eva Kagenaar,&nbsp;David G. Lugo-Palacios,&nbsp;Ajay Aggarwal,&nbsp;John Edwards,&nbsp;Corinne Finn-Faivre","doi":"10.1016/j.lungcan.2026.108975","DOIUrl":"10.1016/j.lungcan.2026.108975","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108975"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5 Serum CEA in Relation to Molecular Changes in Non-Small Cell Lung Cancer","authors":"Ersan Al Zamel ,&nbsp;Heeranand Heeranand ,&nbsp;Mohamad Tayeb ,&nbsp;Abdullah Tayeb","doi":"10.1016/j.lungcan.2026.108955","DOIUrl":"10.1016/j.lungcan.2026.108955","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"212 ","pages":"Article 108955"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147395109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}